| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| Targets |
HDAC6
|
|---|---|
| ln Vitro |
QTX125 (82-48% hours; 25-500 nM) Annexin V/propidium iodide double staining and the cleavage of caspase-9, caspase-8, caspase-3, and PARP demonstrate that TFA administration causes subsequent apoptosis [1]. Using QTX125 TFA (10 nM, 10 μM, and 100 μM), MCL cell lines MINO, REC-1, IRM-2, and HBL-2 cells exhibit dose-dependent hyperacetylation of α-tubulin [1]. When it comes to Burkitt cell lymphoma, follicular lymphoma, and mantle cell lymphoma (MCL), QTX125 TFA exhibits the greatest growth inhibitory impact [1].
|
| ln Vivo |
In nude mice xenografts of REC-1 or MINO cells, QTX125 TFA (60 mg/kg; i.p.; daily for 5 days; 4 weeks) therapy reduces tumor growth [1].
|
| Cell Assay |
Apoptosis Analysis[1]
Cell Types: MINO, REC-1, IRM-2 and HBL-2 cells Tested Concentrations: 25 nM, 50 nM, 100 nM, 500 nM Incubation Duration: 24 hrs (hours), 48 hrs (hours) Experimental Results: Inhibited annexin V/propidium iodide double staining. Western Blot Analysis[1] Cell Types: MINO, REC-1, IRM-2 and HBL-2 cells Tested Concentrations: 25 nM, 50 nM, 100 nM, 500 nM Incubation Duration: 24 hrs (hours) Experimental Results: Inhibited the cleavage of caspase-9, caspase-8, caspase-3, and PARP. |
| Animal Protocol |
Animal/Disease Models: Nude mice bearing REC-1 or MINO cells[1]
Doses: 60 mg/kg Route of Administration: intraperitoneal (ip)administration; daily dosing for 5 days; for 4 weeks Experimental Results: Inhibited tumor growth in REC-1 or MINO cells xenografted in nude mice. |
| References |
| Molecular Formula |
C25H20F3N3O7
|
|---|---|
| Molecular Weight |
531.44
|
| CAS # |
2989537-78-0
|
| Related CAS # |
QTX125;1279698-31-5
|
| Appearance |
Off-white to gray solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~125 mg/mL (~235.21 mM)
H2O :< 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.91 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.91 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8817 mL | 9.4084 mL | 18.8168 mL | |
| 5 mM | 0.3763 mL | 1.8817 mL | 3.7634 mL | |
| 10 mM | 0.1882 mL | 0.9408 mL | 1.8817 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
